Pyxis Oncology Announces 2024 Annual Meeting of Stockholders on June 11

Ticker: PYXS · Form: DEF 14A · Filed: 2024-04-26T00:00:00.000Z

Sentiment: neutral

Topics: Pyxis Oncology, Annual Meeting, Proxy Statement, Director Election, Auditor Ratification

TL;DR

<b>Pyxis Oncology will hold its 2024 virtual Annual Meeting of Stockholders on June 11, 2024, to elect directors and ratify auditors.</b>

AI Summary

Pyxis Oncology, Inc. (PYXS) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Pyxis Oncology, Inc. will hold its 2024 Annual Meeting of Stockholders on June 11, 2024, at 10:00 a.m. Eastern Standard Time. The meeting will be conducted virtually to enable broader participation and reduce costs. Stockholders must register at www.proxydocs.com/PYXS to attend and vote. Key agenda items include the election of four directors (one Class I, three Class III) and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024. The company is a pharmaceutical preparations company incorporated in Delaware with its principal executive offices in Boston, MA.

Why It Matters

For investors and stakeholders tracking Pyxis Oncology, Inc., this filing contains several important signals. The virtual format aims to increase stockholder participation and decrease meeting costs, potentially leading to more engaged governance. The election of directors and ratification of auditors are standard corporate governance procedures crucial for company oversight and financial integrity.

Risk Assessment

Risk Level: low — Pyxis Oncology, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Stockholders should review the director nominees and auditor ratification proposals to make informed voting decisions at the June 11th meeting.

Key Numbers

June 11, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
10:00 a.m. Eastern Standard Time — Meeting Time (2024 Annual Meeting of Stockholders)
2024 — Fiscal Year (Independent registered public accounting firm for the fiscal year ending December 31, 2024)
1 — Class I Director Nominee (Election of one Class I director)
3 — Class III Director Nominees (Election of three Class III directors)

Key Players & Entities

Pyxis Oncology, Inc. (company) — Registrant
June 11, 2024 (date) — Date of Annual Meeting
Ernst & Young LLP (company) — Independent registered public accounting firm
Boston, Massachusetts (location) — Business Address
02118 (location) — ZIP Code
1934 Act (regulatory) — SEC Act
DE (location) — State of Incorporation
1231 (date) — Fiscal Year End

FAQ

When did Pyxis Oncology, Inc. file this DEF 14A?

Pyxis Oncology, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Pyxis Oncology, Inc. (PYXS).

Where can I read the original DEF 14A filing from Pyxis Oncology, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Pyxis Oncology, Inc..

What are the key takeaways from Pyxis Oncology, Inc.'s DEF 14A?

Pyxis Oncology, Inc. filed this DEF 14A on April 26, 2024. Key takeaways: Pyxis Oncology, Inc. will hold its 2024 Annual Meeting of Stockholders on June 11, 2024, at 10:00 a.m. Eastern Standard Time.. The meeting will be conducted virtually to enable broader participation and reduce costs.. Stockholders must register at www.proxydocs.com/PYXS to attend and vote..

Is Pyxis Oncology, Inc. a risky investment based on this filing?

Based on this DEF 14A, Pyxis Oncology, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.

What should investors do after reading Pyxis Oncology, Inc.'s DEF 14A?

Stockholders should review the director nominees and auditor ratification proposals to make informed voting decisions at the June 11th meeting. The overall sentiment from this filing is neutral.

Risk Factors

Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
Virtual Meeting Format [low — operational]: Ensuring smooth technical execution and accessibility for all stockholders participating in the virtual meeting is critical.
Auditor Independence and Effectiveness [low — financial]: The ratification of Ernst & Young LLP as independent auditors is essential for maintaining financial reporting integrity.

Key Dates

2024-06-11: 2024 Annual Meeting of Stockholders — Key date for voting on director elections and auditor ratification.
2024-04-26: Filing Date — Date the Definitive Proxy Statement (DEF 14A) was filed with the SEC.

Filing Stats: 4,734 words · 19 min read · ~16 pages · Grade level 10.2 · Accepted 2024-04-26 16:15:36

Key Financial Figures

$0.001 — 0 shares of our common stock, par value $0.001 per share, were outstanding. Only holde

Filing Documents

2024_pyxs-14a.htm (DEF 14A) — 711KB
img107367540_0.jpg (GRAPHIC) — 29KB
img107367540_1.jpg (GRAPHIC) — 17KB
img107367540_2.jpg (GRAPHIC) — 40KB
img107367540_3.jpg (GRAPHIC) — 64KB
img107367540_4.jpg (GRAPHIC) — 17KB
img107367540_5.jpg (GRAPHIC) — 1668KB
img107367540_6.jpg (GRAPHIC) — 224KB
0000950170-24-049154.txt ( ) — 3548KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION   19 PROPOSAL TWO: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024   26

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   28 ADDITIONAL INFORMATION   30   PYXIS ONCOLOGY, INC.   321 Harrison Avenue Boston, Massachusetts 02118   ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 11, 2024   PROXY STATEMENT   GENERAL INFORMATION This proxy statement is furnished to stockholders of Pyxis Oncology, Inc. (“we,” “us,” “our,” the “Company” or “Pyxis Oncology”), a Delaware corporation, in connection with the solicitation of proxies by our board of directors (the “Board”) for use at our 2024 Annual Meeting of stockholders to be held on June 11, 2024 (the “Annual Meeting”), and at any adjournment or postponement thereof. The Annual Meeting will be held at 10:00 a.m. Eastern Standard Time in a virtual meeting format. In order to attend the Annual Meeting, you must register at www.proxydocs.com/PYXS . Upon completing your registration, you will receive further instructions via email, including a unique link that will allow you access to the Annual Meeting and to vote and submit questions during the Annual Meeting. As permitted by the rules of the U.S. Securities and Exchange Commission (the “SEC”), we are making this proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 available to our stockholders electronically via the Internet at www.proxydocs.com/PYXS. You will be asked to enter the control number located on your proxy card or Notice of Internet Availability of Proxy Materials (“Internet Notice”). On or about May 2, 2024, we will mail to our stockholders the Internet Notice, containing instructions on how to access this proxy statement and vote online or by telephone. If you received an Internet Notice by mail, you will not receive a printed copy of the proxy